Regentis Biomaterials Ltd. · AMEX:RGNT
Regentis Biomaterials — IPO Roadshow (May 2026)
26 slides from Regentis Biomaterials's IPO roadshow presentation, May 29, 2026
Slide 1: Investor Presentation May 2026
Investor Presentation May 2026 Filed Pursuant to Rule 433 Issuer Free Writing Prospectus May 29, 2026 Relating to Preliminary Prospectus Dated May 1, 2026 Registration No. 333-295510
Slide 2: Disclaimer
2 Disclaimer This presentation highlights information about Regentis Biomaterials Ltd. ("Regentis," "we," "us," or the "Company") and the proposed public offering to which this presentation relates. Because this presentation is a summary, it does not contain all of the information that you should co
Slide 3: Forward Looking Statements
3 Forward Looking Statements This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contai
Slide 4: Knee cartilage repair large market with unmet need
4 Knee cartilage repair large market with unmet need U.S. market: 472,500+ procedures annually Limitations: Microfracture (MFx) the current gold standard of care • Short-term relief • Often requires repeat surgical intervention GelrinC® Acellular, unique hydrogel for off- the-shelf knee cartilage re
Slide 5: Company at a Glance
5 Regenerative medicine company developing GelrinC for knee cartilage injuries Ready-to-use hydrogel technology offering cost-effective, restorative tissue repair, sustained pain relief and improved function Phase II success with approximately 100% greater KOOS (1) and VAS (2) improvement vs. microf
Slide 6: Strategic & Clinical Milestones Since IPO
6 Strategic & Clinical Milestones Since IPO Feb 2026 Runway Exited 2025 with $7.4M cash used mainly to complete Phase III and initiate 2026 EU rollout Feb 2026 Leadership Appointed CFO and a Chief Medical Officer with prior experience supporting FDA approval of a cartilage repair product Jan 2026 Cl
Slide 7: Technology & Scale-Up, Commercial Readiness (2026 EU Launch)
7 Technology & Scale-Up Commercial Readiness (2026 EU Launch) Clinical & Regulatory Operational Progress & Commercial Readiness • Network Scaling: Rapidly expanding U.S. Phase III sites and EU footprint (Italy, Eastern Europe)(1) • Data Superiority: Driving long- term durability narrative; developed
Slide 8: 750,000 arthroscopic knee procedures; ~472,500 with cartilage damage
8 750,000 arthroscopic knee procedures 60-66% (~472,500) have cartilage damage ~472,500 procedures The Gelrin platform targets additional significant markets including osteoarthritis and other cartilage injuries in the ankle, wrist, and elbow 8 Initial U.S. Addressable(1) Market 60-66% (~472,500) h
Slide 9: Advantages of GelrinC
9 Advantages of GelrinC® (further supported by the Phase II- study) Off-the-shelf product for cartilage repair New class of acellular solution leveraging: • Polyethylene glycol (PEG) hydrogel implant to drive new cartilage formation • Denatured fibrinogen-controlled erosion enabling hyaline-like car
Slide 10: Testimonial: Dr. Brian Cole
10 Testimonial: Dr. Brian Cole Leading orthopaedic surgeon at Rush Hospital Center, Chicago
Slide 11: Testimonial: Jason M. Scopp, MD
11 Testimonial: Jason M. Scopp, MD Orthopaedic surgeon – Director Peninsula Orthopaedic Associates, Maryland
Slide 12: Regentis
SRegentis
Slide 13: GelrinC vs. competing cartilage repair products
13 Resorbable Hydrogel GelrinC Cell-based Products (Maci of Vericel) Pre-formed Bi-phasic plugs (AgiliC of Cartiheal) Type of Lesion All Types – involving multiple areas of the cartilage Limited - small, well-defined region of the cartilage Limited - small, well-defined region of the cartilage Proce
Slide 14: FDA approved IDE clinical protocol and study design
14 Unique FDA approved IDE Clinical Protocol Phase II Phase III CE Mark EU Approved FDA Allowed use of Historical Control Tigenix for PMA Clinical Study Study Design Highlights • 80 patients needed for submission • Over 50% of patients recruited and treated to date • FDA allowed the use of Historica
Slide 15: KOOS & VAS Results
15 KOOS & VAS Results Near- and long-term improvements superior to microfracture. KOOS scores ~100% greater pain reduction at 2 years. KOOS Scores (Aprrox.) GelrinC: 28 at 2 years vs. Microfracture: 14 at 2 years MRI MOCART Scores GelrinC scores reached 80+ within 24 months. Study Size • 56 patients
Slide 16: EU Phase II - Clinical Results: KOOS
16 EU Phase II - Clinical Results KOOS Measurement – 4 Year Efficacy Data demonstrated P<0.05(1) for 6-24 months compared to microfracture • Safe - Low incidence of Adverse Events (equivalent to microfracture alone) • Efficacy – Approx. 100% superiority improvement of Overall KOOS (2) score change o
Slide 17: EU Phase II - Clinical Results: MOCART Scores
17 EU Phase II - Clinical Results MOCART Scores(1) MOCART (Magnetic resonance Observation of Cartilage Repair Tissue) is a recognized nine-part assessment of cartilage repair based on MRI images Data from GelrinC MRI results P<0.05 in MOCART continues(2) We believe Regentis is the world's first to e
Slide 18: GelrinC Phase III Pivotal Trial Protocol Summary
18 18 Progress 50%+ of 80 patients already recruited and treated with 24- month follow-up No serious adverse events observed Timelines Complete recruitment in Q3 2026 PMA submission to start- end of 2027 Patient Match First 40 patients closely match control group; high likelihood of efficacy in futu
Slide 19: Gelrin Technology Platform: Potential Additional Applications
19 Gelrin Technology Platform Potential Additional Applications May address osteoarthritis and other cartilage injuries in the ankle, wrist, and elbow, based on animal studies 19 GelrinP • A paste form of GelrinC, cured with UV light • Designed for treating injuries in smaller joints (ankle, wrist,
Slide 20: Granted & issued patents
20 27 Granted & issued patents 6: U.S. patents 21: Foreign patents(1) 4 Pending patent applications Patents for Composition of Matter and treatment • Claims protein-polymer conjugates of extracellular matrix proteins (e.g., fibrinogen) or serum proteins (e.g., albumin) • Conjugates are covalently bo
Slide 21: Management: Dr. Galit Reske and Ehud Geller
21 Dr. Galit Reske, PhD Chief Medical Officer • Over 15 years of global experience in clinical development, regulatory strategy, and operations across the U.S., Europe, and Israel • Former Director of Clinical Operations at CartiHeal; instrumental in securing U.S. FDA approval for the Agili-C cartil
Slide 22: Board of Directors
22 Ehud Geller, PhD, MBA Chairman • Former President & CEO of Interpharm Laboratories and EVP of Teva Group • Former head of the Israeli Pharmaceutical Manufacturers Association • Board member of the Tel Aviv Stock Exchange • National Industry award for contribution to biotech industry and managemen
Slide 23: Pre-Offering Capitalization Table
23 Pre-Offering Capitalization Table Fully Diluted Shares Outstanding 6,752,494 Warrants (WAEP: $4.69) 505,322 Options (WAEP: $1.28)(1) 1,067,794 Shares Outstanding 5,179,378 (1) Weighted average exercise price as converted from NIS to USD using the effective exchange rate of 3 NIS per 1.00 USD as o
Slide 24: Summary Financial Statements
24 Summary Financial Statements Summary Income Statement (In USD Thousands) Year Ended December 31, 2025 Year Ended December 31, 2024 Research and development expenses, net: Horizon 2020 Grant $ - $ 2,306 Research and development expenses (331) (662) General and administrative expenses (6,637) (712)
Slide 25: The Only Restorative Solution for Cartilage Repair
25 The Only Restorative Solution for Cartilage Repair Knee cartilage repair large market with unmet need U.S. market: 472,500+ procedures annually Limitations: Microfracture (MFx) the current gold standard of care • Short-term relief • Often requires repeat surgical intervention GelrinC® Acellular h
Slide 26: Thank you
® Kegentis Thank you